Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients – – Gemini could potentially ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 ...

Title : APG990, a monoclonal antibody targeting OX40L, demonstrates safety and an extended half-life in healthy subjects (P3237) Presenter : Carl Dambkowski, M.D., Chief Medical Officer, Apogee ...

Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, today announces encouraging second interim ...

Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) — A randomized Phase II trial from National Taiwan University Hospital reports early ...

The Cyprus Development Bank (CDB bank) on Thursday issued a clarification regarding media reports suggesting that the company may be the subject of an acquisition.“There is nothing specific to ...